CI Stock Recent News

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cigna (CI) have what it takes?

The Cigna Group's risk/reward is balanced after a rebound; I rate it Hold—worth keeping if owned, but not a compelling buy right now. The Evernorth pharmacy benefits arm drives growth, but regulatory risk and insurance challenges keep me cautious until a clearer catalyst emerges. Cigna's fundamentals are solid—growing earnings, strong cash flow, shareholder returns—but the stock is fairly valued versus peers, not a bargain.

Cigna trades at a significant discount to the S&P 500, offering a higher yield and faster dividend growth, making it attractive for total return investors. CI's robust earnings growth is fueled by its Evernorth and Healthcare segments, with strong results and promising exposure to the booming GLP-1 drug market. Management targets 10-14% annual EPS growth, supported by aggressive share buybacks and a safe, growing dividend nearly double the S&P 500 yield.

We prefer to buy and hold stocks with a significant margin of safety. Today, we're highlighting a global tech and e-commerce juggernaut, the leading life sciences REIT, and a major managed healthcare and insurance company. The stocks are priced 20% to 38% below our fair value estimates.

CI's commercial focus and clearer outlook set it apart as UNH faces guidance pulls, CEO change and rising medical costs.

Nonprofits are encouraged to apply now for 2025 funding The Cigna Group Foundation committed $9 million in 2024 to address veteran mental health, distributing $3 million each year through 2026 In first year, 23 grantees were awarded grants to help local veterans feel stable where they live, create positive impact on their mental health BLOOMFIELD, Conn. , July 8, 2025 /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), announced today a new round of grants aimed at improving the mental health of military veterans.

CI to cover RhinAer for chronic rhinitis starting Sept. 15, expanding access to a minimally invasive, office-based treatment.

BLOOMFIELD, Conn. , June 30, 2025 /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), today announced its second round of grant recipients supporting youth mental health.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinAer® treatment of the posterior nasal nerve (CPT 31242), effective September 15, 2025. This change removes RhinAer from Cigna's list of procedures deemed experimental, investigational, and unproven, marking a significant step forward in expanding access to a best-in-class treatment option for patien.

Rising premiums, ongoing technological innovation and the growing demand for Medicare plans are anticipated to propel the performance of the Zacks Medical-HMO industry players. CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.